{"page":{"totalFilteredElements":74},"studies":[{"active":true,"description":"Sequential or up-front triple treatment with durvalumab, tremelimumab and bevacizumab<br />for non-resectable hepatocellular carcinoma (HCC) patients (MONTBLANC)","eudractNumber":"2022-001201-48","id":8455,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"}],"mutations":[],"nctNumber":"NCT05844046","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2023-10-10T10:57:44+02:00","shortTitle":"MONTBLANC","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"Machbarkeitsstudie zu Einfluss des intestinalen Mikrobioms auf die Anastomosenheilung nach chirurgischer Resektion beim Rektumkarzinom","eudractNumber":null,"id":10461,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2025-01-28T12:44:44+01:00","shortTitle":"MikroRectum","therapeutical":false,"therapyLines":[]},{"active":true,"description":"<p class=\"MsoNormal\">ENCLOSE (Klinische Studiengruppe NAFLD): CK18 M30 als\nnicht-invasiver Marker f&#252;r subklinische Zellsch&#228;digung &#8211; prospektive Analyse\ndes Langzeitverlaufes bei NAFLD</p>","eudractNumber":null,"id":2266,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"}],"mutations":[{"name":"Caspase-cleaved fragment of CK18 (M30)","id":"mt_271"}],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2016-07-01T09:43:30+02:00","shortTitle":"NAFLD CSG","therapeutical":false,"therapyLines":[]},{"active":true,"description":"<p class=\"MsoNormal\" align=\"center\" style=\"text-align:left;\">Pr&#228;diktion des\nAnsprechens auf Hypertherme Intraperitoneale Chemotherapie in gastrointestinalen Krebserkrankungen (Hi-STEP1)</p><p class=\"MsoNormal\" align=\"center\" style=\"text-align:left;\">DRKS00028836</p>","eudractNumber":null,"id":10899,"indications":[{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio2","name":"Karzinom des gastrooesophagealen Übergangs"},{"id":"gio3","name":"Magenkarzinom"},{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2025-07-06T09:06:56+02:00","shortTitle":"NCT Hi-STEP1","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"<p class=\"MsoNormal\" style=\"line-height:normal;\">National Center for Tumor Diseases / German Cancer Consortium (NCT/DKTK) Molecularly Aided Stratification for Tumor Eradication Research (MASTER)</p><p class=\"MsoNormal\" style=\"line-height:normal;\"><b>NCT MASTER Program</b></p>","eudractNumber":null,"id":4421,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"},{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio3","name":"Magenkarzinom"},{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"},{"id":"nen","name":"Bösartige Tumoren der Nebenniere"},{"id":"sar","name":"Sarkome"},{"id":"sar1","name":"Knochensarkome (Ewing-Sarkom, Osteosarkom etc.)"},{"id":"sar2","name":"Weichteilsarkome (Liposarkom, Leiomyosarkom, etc.)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2018-01-01T09:51:10+01:00","shortTitle":"NCT-Studie: MASTER Programm","therapeutical":true,"therapyLines":[]},{"active":true,"description":"Prospektive Beobachtungsstudie mit Erstellung einer Biodatenbank zur Untersuchung potentieller Biomarker f&#252;r Risikostratifizierung, Therapiesteuerung und Vertr&#228;glichkeit in Patient*innen mit neuroendokrinen Neoplasien (NENReg)","eudractNumber":null,"id":11499,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"},{"id":"pro","name":"Prostatakrebs"},{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio1","name":"Karzinom der Speiseröhre (Oesophaguskarzinom, inkl. gastrooesophagealer Übergang)"},{"id":"gio2","name":"Karzinom des gastrooesophagealen Übergangs"},{"id":"gio3","name":"Magenkarzinom"},{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"},{"id":"hno","name":"Kopf/Hals Tumoren"},{"id":"hno1","name":"Mundhöhlenkarzinom, Rachenkarzinom, inkl. Mundboden- und Zungengrundkarzinom"},{"id":"hno2","name":"Kehlkopfkrebs (Larynxkarzinom)"},{"id":"nen","name":"Bösartige Tumoren der Nebenniere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2025-11-01T09:14:44+01:00","shortTitle":"NENReg","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Patientendatenintegrationsplattform der Pancreatic Cancer Alliance Bavaria (PCAB)","eudractNumber":null,"id":10521,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2023-05-26T12:31:40+02:00","shortTitle":"PCAB (Pankreasregister)","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Pr&#228;vention von fr&#252;hen Darmkrebserkrankungen - PEARL","eudractNumber":null,"id":11520,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"}],"mutations":[],"nctNumber":"NCT05541601","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2022-10-10T09:48:39+02:00","shortTitle":"PEARL","therapeutical":false,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"<div>PERSUASION</div><div>New Prospective Expanded German Registry of Incidental Gallbladder Carcinoma (PERSUASION) a permanent platform including all kind of biliary tract cancers (BTC)</div>","eudractNumber":null,"id":9177,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"}],"mutations":[],"nctNumber":"NCT04896931","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2023-01-30T21:22:13+01:00","shortTitle":"PERSUASION","therapeutical":false,"therapyLines":[]},{"active":true,"description":"A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Trial of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Treatment-Naive Metastatic Pancreatic Ductal Adenocarcinoma","eudractNumber":"2024-513317-12-00","id":9932,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-04-30T09:54:54+02:00","shortTitle":"PRISM-1","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]}]}